BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position
You may also be interested in...
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003